"Relevance of granulocyte apoptosis to resolution of inflammation at the respiratory mucosa"

Mucosal Immunology

Volumn 1, Issue 5, 2008, Pages 350-363

  Leitch, A E ^a   Duffin, R ^a   Haslett, C ^a   Rossi, A G ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; GLUCOCORTICOID; INTERLEUKIN 5 ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; OMALIZUMAB; PITRAKINRA; STEROID; THEOPHYLLINE;

ACUTE LUNG INJURY; ADJUVANT THERAPY; ADRENAL SUPPRESSION; ADULT RESPIRATORY DISTRESS SYNDROME; APOPTOSIS; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CYSTIC FIBROSIS; DISEASE MODEL; EOSINOPHIL; FIBROSING ALVEOLITIS; GRANULOCYTE; GRANULOCYTE FUNCTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LUNG ALVEOLUS MACROPHAGE; LUNG GAS EXCHANGE; MOLECULAR INTERACTION; MUCOSAL IMMUNITY; NEUTROPHIL; NONHUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; PEPTIC ULCER; PHAGOCYTOSIS; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; RESPIRATORY TRACT MUCOSA; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION;

EID: 50149110086     PISSN: 19330219     EISSN: None     Source Type: Journal    
DOI: 10.1038/mi.2008.31     Document Type: Review

References (112)

1. Seaton, A., Seaton, D. & Leitch, A.G. Crofton and Douglas's respiratory diseases. 5th edn, (Blackwell Science, 2000).
2. Rather, L.J. Disturbance of function (functio laesa): The legendary fifth cardinal sign of inflammation, added by Galen to the four cardinal signs of celsus. Bull NY Acad. Med. 47, 303-322 (1971).
3. Sabroe, I. & Whyte, M.K. Toll-like receptor (TLR)-based networks regulate neutrophilic inflammation in respiratory disease. Biochem. Soc. Trans. 35, 1492-1495 (2007).
4. Rossi, A.G., Hallett, J.M., Sawatzky, D.A., Teixeira, M.M. & Haslett, C. Modulation of granulocyte apoptosis can influence the resolution of inflammation. Biochem. Soc. Trans. 35, 288-291 (2007).
5. Serhan, C.N. et al. Resolution of inflammation: State of the art, definitions and terms. FASEB. J. 21, 325-332 (2007).
6. von Kockritz-Blickwede, M. et al. Phagocytosis-independent antimicrobial activity of mast cells by means of extracellular trap formation. Blood 111, 3070-3080 (2008):
7. Brinkmann, V. et al. Neutrophil extracellular traps kill bacteria. Science 303, 1532-1535 (2004).
8. Nathan, C. Neutrophils and immunity: Challenges and opportunities. Nat. Rev. Immunol. 6, 173-182 (2006).
9. Holgate, S.T. The future of lung research in the UK. Thorax 62 1028-1032 (2007).
10. British Thoracic Society. Health Select Committee inquiry into Health InequalitiesSubmission from the British Thoracic Society-08.01.08 (2008).
11. Lachmann, P.J. Microbial subversion of the immune response. Proc. Natl. Acad. Sci. USA. 99, 8461-8462 (2002).
12. Prince, L.R. et al. Subversion of a lysosomal pathway regulating neutrophil apoptosis by a major bacterial toxin, pyocyanin. J. Immunol. 180, 3502-3511 (2008).
13. Haslett, C. Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am. J. Respir. Crit. Care. Med. 160, S5-11 (1999).
14. Sasmono, R.T. et al. Mouse neutrophilic granulocytes express mRNA encoding the macrophage colony-stimulating factor receptor (CSF-1R) as well as many other macrophage-specific transcripts and can transdifferentiate into macrophages in vitro in response to CSF-1. J. Leukoc. Biol. 82, 111-123 (2007).
15. Araki, H. et al. Reprogramming of human postmitotic neutrophils into macrophages by growth factors. Blood 103, 2973-2980 (2004).
16. Oferman, J.T. Life and death during hematopoietic differentiation. Curr. Opin. Immunol. 19, 491-502 (2007).
17. Rossi, A.G. et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Na Med. 12, 1056-1064 (2006).
18. Sundaramurthy, V. & Pieters, J. Interactions of pathogenic mycobacteria with host macrophages. Microbes Infect. 9, 1671-1679 (2007).
19. Brinkmann, V. & Zychlinsky, A. Beneficial suicide: Why neutrophils die to make NETs. Nat. Rev. Microbiol. 5, 577-582 (2007).
20. Rothenberg, M.E. & Hogan, S.P. The eosinophil. Annu. Rev. Immunol. 24, 147-174 (2006).
21. Perretti, M. & Solito, E. Annexin 1 and neutrophil apoptosis. Biochem. Soc. Trans. 32, 507-510 (2004).
22. Scannell, M. et al. Annexin-1 and peptide derivatives are released by apoptotic cells and stimulate phagocytosis of apoptotic neutrophils by macrophages. J. Immunol. 178, 4595-4605 (2007).
23. Bianchi, S.M., Dockrell, D.H., Renshaw, S.A., Sabroe, I. & Whyte, M.K. Granulocyte apoptosis in the pathogenesis and resolution of lung disease. Clin. Sci. 110, 293-304 (2006).
24. Maianski, N.A., Roos, D. & Kuijpers, T.W. Tumor necrosis factor alpha induces a caspase-independent death pathway in human neutrophils. Blood 101, 1987-1995 (2003).
25. Simon, H.U. Neutrophil apoptosis pathways and their modifications in inflammation. Immunol. Rev. 193, 101-110 (2003).
26. Cowburn, A.S., White, J.F., Deighton, J., Walmsley, S.R. & Chilvers, E.R. z-VAD-fmk augmentation of TNF alpha-stimulated neutrophil apoptosis is compound specific and does not involve the generation of reactive oxygen species. Blood 105, 2970-2972 (2005).
27. Simon, H.U. Regulation of eosinophil and neutrophil apoptosis - similarities and differences. Immunol. Rev. 179, 156-162 (2001).
28. Simon, H.U. Molecules involved in the regulation of eosinophil apoptosis. Chem. Immunol. Allergy 91, 49-58 (2006).
29. Simon, H. & Alam, R. Regulation of eosinophil apoptosis: Transduction of survival and death signals. Int. Arch. Allergy Immunol. 118, 7-14 (1999).
30. Daigle, I. & Simon, H.U. Critical role for caspases 3 and 8 in neutrophil but not eosinophil apoptosis. Int. Arch. Allergy Immunol. 126, 147-156 (2001).
31. Ochiai, K., Kagami, M., Matsumura, R. & Torhioka, H. IL-5 but not interferon-gamma (IFN-gamma) inhibits eosinophil apoptosis by up-regulation of bcl-2 expression. Clin. Exp. Immunol. 107, 198-204 (1997).
32. Weinmann, P., Gaehtgens, P. & Walzog, B. Bcl-XI- and Bax-alpha-mediated regulation of apoptosis of human neutrophils via caspase-3. Blood 93, 3106-3115 (1999).
33. Dzhagalov, I., St John, A. & He, Y.W. The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages. Blood 109, 1620-1626 (2007).
34. Hamasak, A. et al. Accelerated neutrophil apoptosis in mice lacking A1-a, a subtype of the bcl-2-related A1 gene. J. Exp. Med. 188, 1985-1992 (1998).
35. Sabroe, I., Dower, S.K. & Whyte, M.K. The role of Toll-like receptors in the regulation of neutrophil migration, activation, apoptosis. Clin. Infect. Dis. 41 (Suppl 7), S421-S426 (2005).
36. Ward, C. et al. NF-kappaB activation is a critical regulator of human granulocyte apoptosis in vitro. J. Biol. Chem. 274, 4309-4318 (1999).
37. Lawrence, T., Gilroy, D.W., Colville-Nash, P.R. & Willoughby, D.A. Possible new role for NF-kappaB in the resolution of inflammation. Nat. Med. 7, 1291-1297 (2001).
38. Pinho, V. et al. Phosphoinositide-3 kinases critically regulate the recruitment and survival of eosinophils in vivo: Importance for the resolution of allergic inflammation. J. Leukoc. Biol. 77, 800-810 (2005).
39. Pinho, V. et al. Tissue- and stimulus-dependent role of phosphatidylinositol 3-kinase isoforms for neutrophil recruitment induced by chemoattractants in vivo. J. Immunol. 179, 7891-7898 (2007).
40. Savill, J. & Haslett, C. Granulocyte clearance by apoptosis in the resolution of inflammation. Semin. Cell. Biol. 6, 385-393 (1995).
41. Sivertson, K.L., Seeds, M.C., Long, D.L., Peachman, K.K. & Bass, D.A. The differential effect of dexamethasone on granulocyte apoptosis involves stabilization of Mcl-1L in neutrophils but not in eosinophils. Cell. Immunol. 246, 34-45 (2007).
42. Heasman, S.J., Giles, K.M., Ward, C., Rossi, A.G., Haslett, C. & Dransfield, I. Glucocorticoid-mediated regulation of granulocyte apoptosis and macrophage phagocytosis of apoptotic cells: Implications for the resolution of inflammation. J. Endocrinol. 178, 29-36 (2003).
43. Serhan, C.N. Resolution phase of inflammation: Novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu. Rev. Immunol. 25, 101-137 (2007).
44. Hallett, J.M., Leitch, A.E., Riley, N.A., Duffin, R., Haslett, C. & Rossi, A.G. Novel pharmacological strategies for driving inflammatory cell apoptosis and enhancing the resolution of inflammation. Trends Pharmacol. Sci. 29, 250-257 (2008).
45. Kobayashi, N. et al. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity 27, 927-940 (2007).
46. Park, S.Y. et al. Rapid cell corpse clearance by stabilin-2, a membrane phosphatidylserine receptor. Cell Death Differ. 15, 192-201 (2008).
47. Park, D. et al. BAI1 is an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/Rac module. Nature 450, 430-434 (2007).
48. Fadok, V.A., Bratton, D.L., Konowal, A., Freed, P.W., Westcott, J.Y. & Henson, P.M. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/ paracrine mechanisms involving TGF-beta, PGE2, PAF. J. Clin. Invest. 101 890-898 (1998).
49. Barnes, P.J. Alveolar macrophages in chronic obstructive pulmonary disease (COPD). Cell. Mol. Biol. 50, Online Pub:OL627-OL637 (2004).
50. Barnes, P.J. New molecular targets for the treatment of neutrophilic diseases. J Allergy Clin. Immunol. 119, 1055-1062 (2007).
51. MacNee, W. Pathogenesis of chronic obstructive pulmonary disease. Clin. Chest Med. 28, 479-513 (2007).
52. Kirkham, P.A., Spooner, G., Rahman, I. & Rossi, A.G. Macrophage phagocytosis of apoptotic neutrophils is compromised by matrix proteins modified by cigarette smoke and lipid peroxidation products. Biochem. Biophys. Res. Commun. 318, 32-37 (2004).
53. Barnes, P.J., Ito, K. & Adcock, I.M. Corticosteroid resistance in chronic obstructive pulmonary disease: Inactivation of histone deacetylase. Lancet 363, 731-733 (2004).
54. Quint, J.K. & Wedzicha, J.A. The neutrophil in chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 119, 1065-1071 (2007).
55. Barnes, P.J. Pathophysiology of asthma. Br. J. Clin. Pharmacol. 42, 3-10 (1996).
56. Busse, W.W., Banks-Schlegel, S. & Wenzel, S.E. Pathophysiology of severe asthma. J. Allergy Clini. Immunol. 106, 1033-1042 (2000).
57. Hanania, N.A. Targeting airway inflammation in asthma: Current and future therapies. Chest 133, 989-998 (2008).
58. Holgate, S.T. et al. Understanding the pathophysiology of severe asthma to generate new therapeutic opportunities. J. Allergy Clin. Immunol. 117, 496-506 (2006).
59. Maddox, L. & Schwartz, D.A. The pathophysiology of asthma. Annu. Rev. Med. 53, 477-498 (2002).
60. Walsh, G.M., Sexton, D.W. & Blaylock, M.G. Corticosteroids, eosinophils and bronchial epithelial cells: New insights into the resolution of inflammation in asthma. J. Endocrinol. 178, 37-43 (2003).
61. Contoli, M. et al. Role of deficient type III interferon-[lambda] production in asthma exacerbations. Nat. Med. 12, 1023-1026 (2006).
62. Uddin, M., Seumois, G., Lau, L.C., Rytila, P., Davies, D.E. & Djukanovic, R. Enhancement of neutrophil function by the bronchial epithelium stimulated by epidermal growth factor. Eur. Respir. J. 31, 714-724 (2008).
63. Flood-Page, P. et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J. Clin. Invest. 112, 1029-1036 (2003).
64. Flood-Page, P.T., Menzies-Gow, A.N., Kay, A.B. & Robinson, D.S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care. Med. 167, 199-204 (2003).
65. Wenzel, S., Wilbraham, D., Fuller, R., Getz, E.B. & Longphre, M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: Results of two phase 2a studies. Lancet 370, 1422-1431 (2007).
66. Bullens, D.M. et al. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir. Res. 7, 135-13 (2006).
67. Meagher, L.C., Cousin, J.M., Seckl, J.R. & Haslett, C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J. Immunol. 156, 4422-4428 (1996).
68. Wenzel, S.E. A different disease, many diseases or mild asthma gone bad? Challenges of severe asthma. Eur. Respir. J. 22, 397-398 (2003).
69. Collard, H.R. et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care. Med. 176, 636-643 (2007).
70. Du Bois, R. & King, T.E. Jr Challenges in pulmonary fibrosis x 5: The NSIP/UIP debate. Thorax 62, 1008-1012 (2007).
71. Hunninghake, G.W. & Schwarz, M.I. State of the Art. Does current knowledge explain the pathogenesis of idiopathic pulmonary fibrosis?; a perspective. Proc. Am. Thorac. Soc. 4, 449-452 (2007).
72. Wallace, W.A., Fitch, P.M., Simpson, A.J. & Howie, S.E. Inflammation-associated remodelling and fibrosis in the lung - a process and an end point. Int. J. Exp. Pathol. 88, 103-110 (2007).
73. Strieter, R.M. What differentiates normal lung repair and fibrosis? Inflammation, resolution of repair, fibrosis. Proc. Am. Thorac. Soc. 5, 305-310 (2008).
74. Chua, F. et al. Mice lacking neutrophil elastase are resistant to bleomycin-induced pulmonary fibrosis. Am. J. Pathol. 170, 65-74 (2007).
75. Kinder, B.W., Brown, K.K., Schwarz, M.I., Ix, J.H., Kervitsky, A. & King, T.E. Jr Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest 133, 226-232 (2008).
76. Abraham, E. Neutrophils and acute lung injury. Crit. Care. Med. 31, S195-S199 (2003).
77. Bellingan, G.J. The pulmonary physician in critical care *6: The pathoqenesis of ALI/ARDS. Thorax 57, 540-546 (2002).
78. Leaver, S.K. & Evans, T.W. Acute respiratory distress syndrome. BMJ 335, 389-394 (2007).
79. Martin, T.R. Interactions between mechanical and biological processes in acute lung injury. Proc. Am. Thorac. Soc. 5, 291-296 (2008).
80. Matthay, M.A. & Zimmerman, G.A. Acute lung injury and the acute respiratory distress syndrome: Four decades of inquiry into pathogenesis and rational management. Am. J. Respir Cell. Mol. Biol. 33, 319-327 (2005).
81. Donnelly, S.C. et al. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet 341, 643-647 (1993).
82. Oeckler, R.A. & Hubmayr, R.D. Ventilator-associated lung injury: A search for better therapeutic targets. Eur. Respir. J. 30, 1216-1226 (2007).
83. British Thoracic Society. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 56 (Suppl 4),IV1-I64 (2001).
84. Droemann, D. et al. Decreased apoptosis and increased activation of alveolar neutrophils in bacterial pneumonia. Chest 117, 1679-1684 (2000).
85. Watson, R.W., Redmond, H.P., Wang, J.H., Condron, C. & Bouchier-Hayes, D. Neutrophils undergo apoptosis following ingestion of Escherichia coli. J. Immunol. 156, 3986-3992 (1996).
86. Cazzola, M., Matera, M.G. & Pezzuto, G. Inflammation - a new therapeutic target in pneumonia. Respiration 72, 117-126 (2005).
87. Confalonieri, M. et al. Hydrocortisone infusion for severe community acquired pneumonia: A preliminary randomized study. Am. J. Respir Crit. Care. Med. 171, 242-248 (2005).
88. Elizur, A., Cannon, C.L. & Ferkol, T.W. Airway inflammation in cystic fibrosis. Chest 133, 489-495 (2008).
89. Sabroe, I. & Whyte, M.K. Incapacitating the immune system in cystic fibrosis. Nat. Med. 13, 1417-1418 (2007).
90. Brodmerkel, C.M. & Vaddi, K. Transgenic animals in inflammatory disease models. Curr Opin. Biotechnol. 14, 652-658 (2003).
91. Guilbault, C., Saeed, Z., Downey, G.P. & Radzioch, D. Cystic fibrosis mouse models. Am. J. Respir. Cell. Mol. Biol. 36, 1-7 (2007).
92. Kips, J.C. et al. Murine models of asthma. Eur. Respir. J. 22, 374-382 (2003).
93. Moeller, A. et al. Models of pulmonary fibrosis. Drug Discov. Today Dis. Models 3, 243-249 (2006).
94. Moore, B.B. & Hogaboam, C.M. Murine models of pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 294, L152-L160 (2008).
95. Renshaw, S.A., Loynes, C.A., Elworthy, S., Ingham, P.W. & Whyte, M.K. Modeling inflammation in the zebrafish: How a fish can help us understand lung disease. Exp. Lung Res. 33, 549-554 (2007).
96. Harrison, J.H. Jr & Lazo, J.S. High dose continuous infusion of bleomycin in mice: A new model for drug-induced pulmonary fibrosis. J. Pharmacol. Exp. Ther. 243, 1185-1194 (1987).
97. Moeller, A., Ask, K., Warburton, D., Gauldie, J. & Kolb, M. The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int. J. Biochem. Cell. Biol. 40, 362-382 (2008).
98. Hardie, W.D., Le Cras, T.D., Jiang, K., Tichelaar, J.W., Azhar, M. & Korfhagen, T.R. Conditional expression of transforming growth factor-alpha in adult mouse lung causes pulmonary fibrosis. Am. J. Physiol. Lung. Cell. Mol. Physiol. 286, L741-L749 (2004).
99. Sime, P.J., Xing, Z., Graham, F.L., Csaky, K.G. & Gauldie, J. Adenovector-mediated gene transfer of active transforming growth factor-beta 1 induces prolonged severe fibrosis in rat lung. J. Clin. Investig. 100, 768-776 (1997).
100. Xing, Z. et al. Gene transfer for cytokine functional studies in the lung: The multifunctional role of GM-GSF in pulmonary inflammation. J. Leukoc. Biol. 59, 481-488 (1996).
101. Kolb, M., Margetts, P.J., Anthony, D.C., Pitossi, F. & Gauldie, J. Transient expression of IL-1 beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J. Clin. Investig. 107 1529-1536 (2001).
102. Miyazaki, Y. et al. Expression of a tumor-necrosis-factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis - a mouse model of progressive pulmonary fibrosis. J. Clin. Investig. 96, 250-259 (1995).
103. Elias, J.A. et al. Transgenic modeling of interleukin-13 in the lung. Chest 123, 339S-345S (2003).
104. Zosky, G.R. & Sly, P.D. Animal models of asthma. Clin. Exp. Allergy 37, 973-988 (2007).
105. Churg, A., Cosio, M. & Wright, J.L. Mechanisms of cigarette smoke-induced COPD: Insights from animal models. Am. J. Physiol. Lung. Cell. Mol. Physiol. 294, L612-L631 (2008).
106. Fujita, M. & Nakanishi, Y. The pathogenesis of COPD: Lessons learned from in vivo animal models. Med. Sci. Monit. 13, RA19-RA24 (2007).
107. Shapiro, S.D. Transgenic and gene-targeted mice as models for chronic obstructive pulmonary disease. Eur. Respir. J. 29, 375-378 (2007).
108. Dos Santos, C.C. Hyperoxic acute lung injury and ventilator-induced/ associated lung injury: New insights into intracellular signaling pathways. Crit. Care. 11, 126-12 (2007).
109. Kabir, K. et al. Characterization of a murine model of endotoxin-induced acute lung injury. Shock 17, 300-303 (2002).
110. Moine, P., Shenkar, R., Kaneko, D., Le Tulzo, Y. & Abraham, E. Systemic blood loss affects NF-kappa B regulatory mechanisms in the lungs. Am. J. Physiol. Lung. Cell. Mol. Physiol. 273, L185-L192 (1997).
111. Bahrami, S. et al. Small-volume fluid resuscitation with hypertonic saline prevents inflammation but not mortality in a rat model of hemorrhagic shock. Shock. 25, 283-289 (2006).
112. London, L., Majeski, E.I., Paintlia, M.K., Harley, R.A. & London, S.D. Respiratory reovirus 1/L induction of diffuse alveolar damage: A model of acute respiratory distress syndrome. Exp. Mol. Pathol. 72 24-36 (2002).